Chile vs Yemen: Statin use vs. average non-HDL cholesterol levels

Chile
3.4
in 2018
Yemen
3.4
in 2018
Chile rank
75th
Yemen rank
75th

Statin use vs. average non-HDL cholesterol levels over time

  • Chile
  • Yemen
01234198019992018

How they compare

Chile currently reports 3.4 against 3.4 in Yemen, a difference of 0.

The two have swapped places 3 times across 39 shared years of data; in 1980 it was Chile ahead.

Chile ranks 75th and Yemen ranks 75th of 191 countries.

Chile has averaged higher in every one of the 4 decades both report.

Head to head by decade

Decade Chile Yemen Difference Ahead
1980s 3.85 3.04 0.81 Chile
1990s 3.82 3.32 0.5 Chile
2000s 3.75 3.48 0.27 Chile
2010s 3.5 3.46 0.0444 Chile

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Chile or Yemen?
Chile, at 3.4 against 3.4 in Yemen as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Chile and Yemen?
0, with Chile ahead.
How many years of comparable data are there for Chile and Yemen?
39 years are reported by both, from 1980 to 2018.
How do Chile and Yemen rank globally for statin use vs. average non-hdl cholesterol levels?
Chile ranks 75th and Yemen ranks 75th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.